JPMorgan raises Cellebrite stock target to $28, keeps Overweight rating
JPMorgan updated its outlook on Cellebrite (NASDAQ:CLBT), increasing the price target to $28 from the previous $24, while retaining an Overweight rating on the stock. Currently trading at $25.29 with ...
JPMorgan’s Barnum Says Focus on Succession ‘as High as Ever’
JPMorgan Chase & Co. Chief Financial Officer Jeremy Barnum said the bank’s board remains focused on succession and has a deep ...